# Lakefront Biotherapeutics (LKFT) — News

LKFT · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/lkft/news

## Recent headlines

- [Lakefront Biotherapeutics NV: Intention to wind down cell therapy activities after review of strategic alternatives is substantially complete](https://www.ainvest.com/news/lakefront-biotherapeutics-nv-intention-wind-cell-therapy-activities-review-strategic-alternatives-substantially-complete-2610) — AInvest Wire, Oct 14, 2026
- [Lakefront Biotherapeutics NV: Terms of deal include upfront payment of EUR 8 mln & potential for up to $230 mln in milestone payments](https://www.ainvest.com/news/lakefront-biotherapeutics-nv-terms-deal-include-upfront-payment-eur-8-mln-potential-230-mln-milestone-payments-2610) — AInvest Wire, Oct 14, 2026
  Lakefront Biotherapeutics NV has announced a licensing agreement that includes an upfront payment of EUR 8 million, with the potential for additional milestone payments totaling up to $230 million. The terms of the deal reflect the company’s strategic focus on advancing its pipeline of therapeutic…
- [Lakefront Biotherapeutics NV: Shares up 3% after RBC upgrades to 'outperform'](https://www.ainvest.com/news/lakefront-biotherapeutics-nv-shares-3-rbc-upgrades-outperform-2609) — AInvest Wire, Sep 23, 2026
- [Lakefront Biopharma NV - Gamgertamig in Phase 2 studies; registration studies expected in 2027](https://www.ainvest.com/news/lakefront-biopharma-nv-gamgertamig-phase-2-studies-registration-studies-expected-2027-2608) — AInvest Wire, Aug 24, 2026
  Lakefront Biotherapeutics NV (Euronext & Nasdaq: LKFT) has announced that gamgertamig (OM336), a clinical-stage BCMAxCD3 T cell engager, is currently in Phase 2 studies and enter registrational studies as early as 2027. The drug candidate, which has been granted both Fast Track and Orphan Drug…
- [Lakefront Biopharma reports half-year 2026 financial results and provides business update](https://www.ainvest.com/news/lakefront-biopharma-reports-year-2026-financial-results-business-update-2608) — AInvest Wire, Aug 10, 2026

---

Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).